Evidence map›Paper›PMID 33011615›Full record

ArticleNeurobiology of aging2020

Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain.

Manu S Goyal, Brian A Gordon, Lars E Couture, Shaney Flores, Chengjie Xiong, John C Morris, Marcus E Raichle, Tammie L-S Benzinger, Andrei G Vlassenko

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Brain aerobic glycolysis and resilience in Alzheimer disease.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Review
  14. Article
  15. Association of aerobic glycolysis with the structural connectome reveals a benefit-risk balancing mechanism in the human brain.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Manu S GoyalNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: goyalm@wustl.edu.
Brian A GordonNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Lars E CoutureNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Shaney FloresNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Chengjie XiongKnight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
John C MorrisDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Marcus E RaichleNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Tammie L-S BenzingerNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Andrei G VlassenkoNeuroimaging Laboratories, Washington University School of Medicine, St. Louis, MO, USA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Washington University in St. Louis · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI Tammie Lee Smith Benzinger · 1985 to 2026
$69.5M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Brian N Finck · 1999 to 2026
$30.2M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
THE XNAT IMAGING INFORMATICS PLATFORMR01EB009352 · NIBIB · WASHINGTON UNIVERSITY · PI Daniel Scott Marcus · 2009 to 2026
$9.3M
Aerobic Glycolysis in the Development ofAlzheimer's DiseaseR01AG053503 · NIA · WASHINGTON UNIVERSITY · PI RAICHLE, MARCUS E, VLASSENKO, ANDREI G. · 2017 to 2021
$4.1M
Aerobic Glycolysis: A Marker of BrainResilience to Aging and Alzheimer's DiseaseR01AG057536 · NIA · WASHINGTON UNIVERSITY · PI GOYAL, MANU S, VLASSENKO, ANDREI G. · 2017 to 2021
$3.7M
Quantification of Neuroinflammation inAlzheimer's Disease Using Diffusion BasisSpectrum ImagingR01AG054567 · NIA · WASHINGTON UNIVERSITY · PI BENZINGER, TAMMIE LEE SMITH, WANG, YONG · 2017 to 2021
$3.6M
NCATS NIH HHS UL1 TR002345NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P50 AG005681NIA NIH HHS R01 AG053503NIA NIH HHS R01 AG054567NIA NIH HHS R01 AG057536NIBIB NIH HHS R01 EB009352NIDDK NIH HHS P30 DK056341
6 · The paper itself

Abstract

In Alzheimer's disease, brain amyloid deposition has a distinct topography that correlates with aerobic glycolysis (AG), that is, the use of glucose beyond that predicted by oxygen consumption. The causes for this relationship remain unclear but might provide crucialinsight into how amyloid deposition begins. Here we develop methods to study the earliest topography of amyloid deposition based on amyloid imaging and investigate its spatiotemporal evolution with respect to the topography of AG in adults. We find that the spatiotemporal dynamics of amyloid deposition are largely explained by 1 factor, defined here as the amyloid topography dissimilarity index (ATDI). ATDI is bimodal, more highly dynamic during early amyloid accumulation, and predicts which individuals will cross a conservative quantitative threshold at least 3-5 years in advance. Using ATDI, we demonstrate that subthreshold amyloid accumulates primarily in regions that have high AG during early adulthood. Our findings suggest that early on-target subthreshold amyloid deposition mirrors its later regional pattern, which best corresponds to the topography of young adult brain AG.

Indexed as

GlycolysisSpatio-Temporal AnalysisAdultAerobiosisAgedAged, 80 and overAlzheimer DiseaseAmyloidogenic ProteinsBrainFemaleHumansMaleMiddle AgedOxygen ConsumptionAmyloidogenic ProteinsAerobic glycolysisAlzheimer's diseaseBrain amyloidPositron emission tomography

Identifiers

PMID33011615
PMCPMC7894981
OpenAlexW3082536621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.